Stock listing
Frankfurt:K27 Kodiak Sciences Inc Aktie
German listing (Frankfurt) of Kodiak Sciences Inc · home listing NASDAQ:KOD
Follow Kodiak Sciences Inc into a list and get an email when it puts out news.
Share price · FWB:K27
€88.64 EUR 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- €88.48 – €88.64 EURNov 20, 2026
- Market cap
- €5.57B EURAt the close on Nov 20, 2026 · price × 62.85M shares outstanding
- 52-week range
- €15.55 – €91.37 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €14,261 EURMedian day 25 shares · 25 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KOD · Home | $97.17 USD | -0.64 (-0.7%) | 692,947 | $97.00 | $100.89 | $96.53 | $97.81 | Close on Nov 20, 2026 |
| Frankfurt:K27 | €88.64 EUR | 0.00 (0.0%) | — | €88.48 | €88.64 | €88.48 | €88.64 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:K27 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €87.49 | +3.901 | +4.7% | €80.60 | €87.71 | €80.00 | 0 | |
| €83.58 | -5.147 | -5.8% | €87.10 | €87.13 | €82.34 | 124 | |
| €88.73 | +0.955 | +1.1% | €87.76 | €88.82 | €86.58 | 124 | |
| €87.78 | +1.848 | +2.2% | €85.81 | €87.98 | €85.53 | 600 | |
| €85.93 | -3.642 | -4.1% | €88.53 | €88.59 | €85.61 | 0 | |
| €89.57 | -1.686 | -1.8% | €89.57 | €89.57 | €89.57 | 2,346 | |
| €91.26 | +10.36 | +12.8% | €86.37 | €91.37 | €86.34 | 143 | |
| €80.90 | +0.311 | +0.4% | €80.90 | €80.90 | €80.90 | 96 | |
| €80.59 | +0.011 | 0.0% | €80.12 | €80.84 | €79.73 | 288 | |
| €80.58 | +5.26 | +7.0% | €78.72 | €81.92 | €78.19 | 288 | |
| €75.32 | -2.01 | -2.6% | €75.32 | €75.32 | €75.32 | 20 | |
| €77.33 | -2.332 | -2.9% | €77.33 | €77.33 | €77.33 | 0 | |
| €79.66 | -4.84 | -5.7% | €81.16 | €81.30 | €78.80 | 100 | |
| €84.50 | +3.702 | +4.6% | €81.86 | €84.52 | €81.60 | 0 | |
| €80.80 | +2.572 | +3.3% | €75.90 | €81.23 | €75.58 | 0 | |
| €78.23 | +1.58 | +2.1% | €78.23 | €78.23 | €78.23 | 0 | |
| €76.65 | -4.683 | -5.8% | €72.86 | €76.76 | €72.66 | 62 | |
| €81.33 | -8.109 | -9.1% | €81.33 | €81.33 | €81.33 | 0 | |
| €89.44 | +0.82 | +0.9% | €89.44 | €89.44 | €89.44 | 2 | |
| €88.62 | +3.219 | +3.8% | €89.70 | €90.69 | €88.25 | 120 | |
| €85.40 | +3.696 | +4.5% | €84.26 | €85.57 | €83.38 | 1,428 | |
| €81.70 | -0.615 | -0.7% | €81.03 | €81.80 | €80.79 | 162 | |
| €82.32 | -0.529 | -0.6% | €82.12 | €82.33 | €82.11 | 0 | |
| €82.85 | -1.896 | -2.2% | €83.10 | €83.10 | €81.32 | 13 | |
| €84.74 | +0.355 | +0.4% | €84.91 | €86.10 | €84.05 | 491 | |
| €84.39 | -3.915 | -4.4% | €87.01 | €87.03 | €80.19 | 120 | |
| €88.30 | +8.468 | +10.6% | €85.25 | €88.38 | €85.19 | 0 | |
| €79.83 | +4.518 | +6.0% | €79.84 | €80.07 | €79.75 | 100 | |
| €75.32 | -3.947 | -5.0% | €75.32 | €75.32 | €75.32 | 296 | |
| €79.26 | +51.35 | +184.0% | €30.93 | €79.28 | €30.87 | 1,326 | |
| €27.91 | +0.516 | +1.9% | €28.57 | €28.65 | €27.81 | 1,076 | |
| €27.40 | +0.055 | +0.2% | €27.39 | €27.51 | €27.22 | 0 | |
| €27.34 | -2.211 | -7.5% | €29.44 | €30.18 | €27.18 | 30 | |
| €29.55 | +1.372 | +4.9% | €28.17 | €29.73 | €28.13 | 332 | |
| €28.18 | +0.437 | +1.6% | €28.55 | €28.63 | €28.17 | 174 | |
| €27.74 | -0.746 | -2.6% | €28.21 | €28.40 | €27.62 | 314 | |
| €28.49 | +0.433 | +1.5% | €28.49 | €28.49 | €28.49 | 0 | |
| €28.06 | -0.36 | -1.3% | €28.06 | €28.06 | €28.06 | 0 | |
| €28.42 | +0.099 | +0.3% | €28.48 | €28.80 | €28.42 | 100 | |
| €28.32 | -0.092 | -0.3% | €27.93 | €28.38 | €27.91 | 170 | |
| €28.41 | +0.031 | +0.1% | €28.02 | €28.70 | €27.93 | 1,528 | |
| €28.38 | -1.025 | -3.5% | €28.38 | €28.38 | €28.38 | 0 | |
| €29.40 | -0.029 | -0.1% | €29.57 | €29.68 | €29.34 | 0 | |
| €29.43 | +0.057 | +0.2% | €28.79 | €29.44 | €28.58 | 0 | |
| €29.38 | -1.351 | -4.4% | €29.38 | €29.38 | €29.38 | 0 | |
| €30.73 | -1.055 | -3.3% | €30.73 | €30.73 | €30.73 | 0 | |
| €31.78 | +0.253 | +0.8% | €31.78 | €31.78 | €31.78 | 0 | |
| €31.53 | -0.028 | -0.1% | €31.53 | €31.53 | €31.53 | 0 | |
| €31.56 | +1.086 | +3.6% | €31.56 | €31.56 | €31.56 | 0 | |
| €30.47 | -2.493 | -7.6% | €31.84 | €31.86 | €30.19 | 100 | |
| €32.96 | -0.411 | -1.2% | €32.96 | €32.96 | €32.96 | 0 | |
| €33.37 | -0.16 | -0.5% | €33.37 | €33.37 | €33.37 | 0 | |
| €33.53 | +2.338 | +7.5% | €33.53 | €33.53 | €33.53 | 0 | |
| €31.20 | -1.033 | -3.2% | €31.20 | €31.20 | €31.20 | 0 | |
| €32.23 | -1.283 | -3.8% | €32.23 | €32.23 | €32.23 | 0 | |
| €33.51 | -0.471 | -1.4% | €33.51 | €33.51 | €33.51 | 114 | |
| €33.98 | -1.567 | -4.4% | €33.94 | €34.06 | €33.91 | 25 |
- Ticker
- Frankfurt:K27
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
Latest deck · Sep 28, 2026
Investor Presentation (September 2026)
Investor deck · 42 slides
Latest news
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
Oct 7, 2026
Closed €82.32 (-0.6%) on Oct 7, 2026
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
Sep 28, 2026
Closed €79.26 (+184.0%) on Sep 28, 2026
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Sep 25, 2026
Closed €79.26 (+184.0%) on Sep 28, 2026
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
Aug 13, 2026
Closed €31.11 (-16.2%) on Aug 14, 2026
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Aug 10, 2026
Closed €36.76 (-5.0%) on Aug 11, 2026
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
Aug 6, 2026
Closed €37.17 (+1.4%) on Aug 6, 2026
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
May 28, 2026
Closed €30.72 (+3.3%) on May 29, 2026
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
May 7, 2026
Closed €35.73 (-8.0%) on May 8, 2026
Kodiak Sciences Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 124 in all · newest Nov 12, 2026 · oldest 2019
- Decks
- 40 decks · latest Sep 28, 2026
Where Kodiak Sciences Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KOD · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2N6P0 | LS Exchange | Germany | EUR |
| gettex:K27 | gettex | Germany | EUR |
| Lang & Schwarz:A2N6P0 | Lang & Schwarz | Germany | EUR |
| BIVA:KOD | BIVA | Mexico | MXN |
| BMV:KOD | BMV | Mexico | MXN |
| BOATS:KOD | BOATS | United States | USD |
| Tradegate:K27 | Tradegate | Germany | EUR |
| Frankfurt:K27 · This page | Frankfurt | Germany | EUR |
| Dusseldorf:K27 | Dusseldorf | Germany | EUR |
| Munich:K27 | Munich | Germany | EUR |
| Stuttgart:K27 | Stuttgart | Germany | EUR |
Valuation
Price/book 505× against a median of 12.5×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $6.31B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 505×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 3.7×
- Beta vs S&P 500
- 1.58
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kodiak Sciences Inc · NASDAQ:KOD | US$6.35B | US$6.31B | n/a | n/a | n/a | 505× | n/a | 3.7× | 1.58 |
| CG Oncology, Inc. · NASDAQ:CGON | US$7.10B | US$6.12B | n/a | 992× | n/a | 7.2× | n/a | 0.0× | 0.83 |
| Cytokinetics, Incorporated · NASDAQ:CYTK | US$7.07B | US$6.36B | n/a | 56.2× | n/a | n/a | −686.6% | n/a | 0.93 |
| Axsome Therapeutics, Inc. · NASDAQ:AXSM | US$6.80B | US$6.68B | n/a | 7.7× | n/a | 64.5× | −18.2% | 1.8× | 0.69 |
| Akeso, Inc. · HKEX:9926 | US$6.66B | US$6.04B | n/a | 13.5× | n/a | 5.2× | −36.4% | 0.6× | n/a |
| Immunovant, Inc. · NASDAQ:IMVT | US$6.57B | US$5.85B | n/a | 825× | n/a | 10.0× | n/a | 0.0× | 1.46 |
| Oruka Therapeutics, Inc. · NASDAQ:ORKA | US$6.50B | US$5.58B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.30 |
| ImmunityBio, Inc. · NASDAQ:IBRX | US$6.40B | US$6.10B | n/a | 33.4× | n/a | n/a | −607.8% | n/a | 1.50 |
| Abivax SA · EURONEXT:ABVX | US$6.05B | US$5.60B | n/a | n/a | n/a | 15.1× | n/a | 0.0× | n/a |
| Scholar Rock Holding Corporation · NASDAQ:SRRK | US$5.87B | US$5.65B | n/a | 9,921× | n/a | 34.8× | n/a | 1.2× | 0.91 |
| Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR | US$5.85B | US$4.66B | n/a | 10.3× | n/a | 116× | −160.6% | 0.0× | 1.34 |
| Median of the others | US$6.54B | US$5.95B | 44.8× | 12.5× | −160.6% | 0.0× | 1.12 |
Forecasts
5 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 129.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.00 · 2 analysts
Team and board
| Director | Role |
|---|---|
| Charles A. Bancroft | Chair of the Audit Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +2.7% |
| Q2 2026 | Aug 13, 2026 · After close | +3.4% |
| Q1 2026 | May 7, 2026 · After close | −6.1% |
| Q4 2025 | Mar 26, 2026 | +62.6% |
| Q3 2025 | Nov 13, 2025 · After close | +3.4% |
| Q2 2025 | Aug 13, 2025 · After close | +16.5% |
| Q1 2025 | May 14, 2025 · After close | −15.5% |
| Q4 2024 | Mar 26, 2025 · Before open | −6.1% |
| Q3 2024 | Nov 14, 2024 · After close | +4.3% |
| Q2 2024 | Aug 14, 2024 · After close | +1.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | 0.0% |
| Q4 2023 | Mar 28, 2024 · Before open | −29.4% |
| Q3 2023 | Nov 14, 2023 · After close | +5.2% |
| Q2 2023 | Aug 14, 2023 · After close | −10.0% |
| Q1 2023 | May 15, 2023 · After close | +10.4% |
| Q4 2022 | Mar 28, 2023 · After close | +23.3% |
| Q3 2022 | Nov 9, 2022 · After close | +5.8% |
| Q2 2022 | Aug 9, 2022 · After close | +14.5% |
| Q1 2022 | May 10, 2022 · After close | −7.6% |
| Q4 2021 | Mar 1, 2022 · After close | +0.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 42 slides | Sep 28, 2026 |
| Investor Presentation (September 2026) | Investor deck | 89 slides | September 2026 |
| Jefferies Global Healthcare Conference 2026 | Conference | 78 slides | June 2026 |
| 44th Annual J.P. Morgan Healthcare Conference (January 2026) | Conference | 99 slides | Jan 12, 2026 |
| Jefferies Global Healthcare Conference – London 2025 | Conference | 74 slides | Nov 17, 2025 |
| Investor Day (July 2025) | Investor day | 120 slides | Jul 16, 2025 |
| International Ocular Inflammation Society 2025 | Conference | 39 slides | 2025 |
| Technical Presentation (2025) | Technical | 8 slides | 2025 |
| 43rd J.P. Morgan Healthcare Conference 2025 | Conference | 78 slides | January 2025 |
| Technical Presentation (2025) | Technical | 32 slides | 2025 |
All 40 decks
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Closed: US$69M raised | Nov 12, 2026 |
| Public offering of common stock Closed: US$184M raised · US$23 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Evercore ISI (co-lead), UBS Investment Bank (co-lead) Use of proceeds: Strengthens financial position through Phase 3 topline readouts for KSI-101, KSI-501 and tarcocimab | Dec 18, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$10.00 a share on Oct 3, 2018.
- Price
- US$10.00 a share
- Shares offered
- 9,000,000 shares of common stock
- Offering size
- US$90 million
- Underwriters' option
- Up to 1,350,000 more shares
- Underwriters
- Morgan Stanley, BofA Merrill Lynch, Barclays, Chardan · In the order on the cover
- Shares delivered
- On or about Oct 9, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 14, 2018 |
| Filed publicly | Sep 7, 2018 |
| Amended 3 times | Newest Oct 1, 2018 |
| Shares registered with an exchange | Oct 1, 2018 |
| Declared effective by the SEC | Oct 3, 2018 |
| Final prospectus, with the price | Oct 5, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 5, 2018 |
| FWP · Free writing prospectus | Oct 4, 2018 |
| EFFECT · Notice that a registration is effective | Oct 3, 2018 |
| CERT · Exchange's certificate of listing | Oct 2, 2018 |
| S-1/A · Registration statement, amended | Oct 1, 2018 |
| CORRESP · Letter to the SEC | Oct 1, 2018 |
| CORRESP · Letter to the SEC | Oct 1, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 1, 2018 |
| CORRESP · Letter to the SEC | Sep 27, 2018 |
| UPLOAD · Letter from the SEC | Sep 25, 2018 |
All 21 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 24, 2018 |
| S-1/A · Registration statement, amended | Sep 24, 2018 |
| UPLOAD · Letter from the SEC | Sep 17, 2018 |
| CORRESP · Letter to the SEC | Sep 14, 2018 |
| S-1/A · Registration statement, amended | Sep 11, 2018 |
| S-1 · Registration statement | Sep 7, 2018 |
| UPLOAD · Letter from the SEC | May 11, 2018 |
| DRSLTR · Letter to the SEC with a draft | Apr 30, 2018 |
| DRS/A · Draft registration statement, amended | Apr 30, 2018 |
| UPLOAD · Letter from the SEC | Mar 13, 2018 |
| DRS · Draft registration statement | Feb 14, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 5, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 26.7M | 25.9M | 11.0M | 8.71M | 4.21M | 911.0K | 490.0K | 549.0K | 257.0K | |
| Gross profit | -26.7M | -25.9M | -11.0M | -8.71M | -4.21M | -911.0K | -490.0K | -549.0K | -257.0K | |
| Research and development | 182.4M | 126.1M | 206.3M | 267.6M | 217.3M | 107.4M | 37.5M | 18.8M | 22.0M | 14.1M |
| Selling, general and administrative | 52.0M | 60.8M | 71.0M | 73.8M | 49.7M | 28.6M | 11.7M | 7.58M | 3.50M | 3.10M |
| Operating income | -234.4M | -186.8M | -277.3M | -341.4M | -267.1M | -136.0M | -49.2M | -26.4M | -25.5M | -17.2M |
| Depreciation and amortization | 18.3M | 18.7M | 18.3M | 3.80M | 1.00M | 477.0K | 538.0K | 490.0K | 549.0K | 257.0K |
| EBITDA | -216.1M | -168.1M | -259.0M | -337.6M | -266.0M | -135.5M | -48.7M | -25.9M | -25.0M | -16.9M |
| Interest expense | 0 | 0 | 13.0K | 18.0K | 47.0K | 25.0K | 8.00K | 5.52M | 1.19M | 6.00K |
| Income before tax | -229.9M | -176.2M | -260.4M | -333.8M | -266.9M | -133.1M | -47.4M | -41.4M | -27.9M | -17.1M |
| Income tax | 52.0K | 20.0K | 33.0K | 33.0K | 74.0K | 14.0K | -638.0K | -9.55M | -45.0K | 31.0K |
| Net income | -230.0M | -176.2M | -260.5M | -333.8M | -267.0M | -133.1M | -47.4M | -41.4M | -27.9M | -17.1M |
| Earnings per share, basic | -4.32 | -3.35 | -4.97 | -6.39 | -5.16 | -2.91 | -1.25 | -2.77 | -3.72 | -2.38 |
| Earnings per share, diluted | -4.32 | -3.35 | -4.97 | -6.39 | -5.16 | -2.91 | -1.25 | -2.77 | -3.72 | -2.38 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 209.9M | 168.1M | 285.5M | 190.4M | 731.5M | 944.4M | 211.8M | 88.3M | 1.40M | 9.62M |
| Short-term investments | 0 | 288.5M | 0 | 24.6M | 124.7M | |||||
| Current assets | 214.8M | 171.9M | 289.3M | 486.0M | 734.8M | 972.0M | 339.2M | 90.4M | 1.59M | 10.2M |
| Property, plant and equipment | 85.3M | 102.2M | 120.5M | 56.4M | 41.3M | 5.14M | 996.0K | 1.10M | 1.51M | 1.78M |
| Total assets | 351.5M | 335.6M | 479.4M | 666.6M | 904.2M | 1.07B | 358.9M | 92.2M | 3.24M | 12.1M |
| Accounts payable | 12.9M | 3.92M | 13.6M | 9.13M | 12.4M | 8.65M | 2.62M | 1.05M | 3.36M | 1.07M |
| Current liabilities | 45.5M | 25.6M | 41.7M | 52.5M | 64.7M | 31.4M | 11.7M | 4.83M | 9.16M | 2.51M |
| Long-term debt | 9.92M | 103.0K | ||||||||
| Total debt | 159.2M | 70.3M | 181.6M | 187.7M | 179.9M | 77.4M | 1.94M | 12.4M | 185.0K | |
| Total liabilities | 194.2M | 185.3M | 213.6M | 230.5M | 240.9M | 206.6M | 13.5M | 5.36M | 22.0M | 53.2M |
| Shareholders' equity | 157.4M | 150.3M | 265.8M | 436.2M | 663.3M | 860.8M | 345.4M | 86.8M | -68.7M | -41.1M |
| Shares outstanding | 61.8M | 52.7M | 52.5M | 52.3M | 51.8M | 51.1M | 44.4M | 36.8M | 7.94M | 44.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -136.0M | -117.3M | -154.2M | -206.5M | -182.3M | -83.4M | -39.1M | -29.0M | -17.7M | -16.0M |
| Capital spending | -506.0K | -375.0K | -41.4M | -37.0M | -17.0M | -3.81M | -437.0K | -78.0K | -209.0K | -771.0K |
| Free cash flow | -136.5M | -117.7M | -195.5M | -243.5M | -199.3M | -87.2M | -39.6M | -29.1M | -17.9M | -16.8M |
| Cash from investing | -506.0K | -755.0K | 249.2M | -336.5M | -38.8M | 104.8M | -137.0M | -581.0K | -209.0K | -771.0K |
| Cash from financing | 178.3M | 501.0K | 31.0K | 1.90M | 8.18M | 717.4M | 299.7M | 116.5M | 9.64M | -120.0K |
| Dividends paid | -7.91M | -10.0M | -6.25M | -2.29M | ||||||
| Share buybacks | 174.0K | 484.0K | -487.0K | -132.0K | 0 | 0 | -4.00K | |||
| Change in cash | 41.8M | -117.6M | 95.1M | -541.1M | -212.9M | 738.8M | 123.5M | 86.9M | -8.23M | -16.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 21, 2026 | Other filings | SEC |
| S-3ASR · Registration statement | Oct 20, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 30, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 2, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 5 · Annual statement of ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 17, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Dec 15, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 19, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 29, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K · Current report | Nov 6, 2023 | Current report | SEC |
| 8-K · Current report | Aug 17, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 8-K · Current report | Jul 24, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2023 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Jun 5, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 31, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 22, 2023 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 18, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 15, 2023 | Other filings | SEC |
| S-3 · Registration statement | May 15, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2023 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 5, 2023 | Other filings | SEC |
| S-3 · Registration statement | Mar 31, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2023 | Results | SEC |
| 5 · Annual statement of ownership | Feb 14, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 3, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 9, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2022 | Results | SEC |
| 8-K · Current report | Aug 8, 2022 | Current report | SEC |
| 4 · Change in ownership | Jul 8, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2022 | Meeting outcome | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 6, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2022 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 18, 2022 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 10, 2022 | Offer document | SEC |
| 8-K · Current report | May 10, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 10, 2022 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2022 | Meeting notice | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 10, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 10, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 9, 2022 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 1, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 1, 2022 | Results | SEC |
| 4 · Change in ownership | Feb 28, 2022 | Insider trade | SEC |
| 8-K · Current report | Feb 23, 2022 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2022 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 4, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 3, 2022 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 31, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2021 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 15, 2021 | Offer document | SEC |
| 4 · Change in ownership | Nov 24, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2021 | Quarterly report | SEC |
This page holds 200 of 427 filings. Open Filings
Cap table
Built by 6ix from Kodiak Sciences Inc’s releases · as of Nov 12, 2026
- Common shares
- 65,395,553
- Fully diluted
- 65,395,553
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 65,395,553 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 65,395,553 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Felix Baker Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past) | Director · Since at least Oct 3, 2018 |
| Julian Baker Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 26, 2006 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past) | Director · Since at least Oct 3, 2018 |
| Richard Levy Other companies: Protara Therapeutics, Inc. (Director · Since at least Jan 9, 2020); Kiniksa Pharmaceuticals International, plc (Director · Since at least Mar 4, 2019); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 19, 2018); Constellation Pharmaceuticals Inc (Director · Apr 3, 2020 – Jul 15, 2021 · Past) | Director · Since at least Oct 3, 2018 |
| Charles A. Bancroft Other companies: Bristol-Myers Squibb Company (EVP, Head of Integration · Dec 31, 2019 – Mar 10, 2020 · Past); Colgate-Palmolive Company (Director · May 13, 2019 – May 13, 2019 · Past) | Chair of the Audit Committee · Since at least Apr 2, 2020 |
| Robert A. Profusek Other companies: CTS Corporation (Director · Since at least Nov 5, 2020); Valero Energy Corporation (Director · Apr 29, 2021 – May 15, 2024 · Past) | Director · Since at least Jun 30, 2021 |
| Taiyin Yang Other companies: Kronos Bio Inc (Director · Since at least Mar 25, 2021); Gilead Sciences, Inc. (SVP, Pharm Dev & Mfg · Jan 25, 2006 – May 8, 2007 · Past) | Director · Since at least Dec 17, 2019 |
| Bassil I. Dahiyat Other companies: Xencor, Inc. (President & Chief Executive Officer, Director · Since at least Dec 2, 2013) | Director · Since at least Oct 3, 2018 |
| Jason Ehrlich | See Remarks · Oct 3, 2018 – Jun 24, 2023 · Past |
| John A Borgeson | Chief Financial Officer · Since at least Oct 3, 2018 |
| Victor Perlroth | Chairman and CEO, Director · Since at least Oct 3, 2018 |
Log in to ask 6ix AI your own questions about Kodiak Sciences Inc.